GW Pharmaceuticals’ cannabis-derived epilepsy drug wins European approval
The European Commission approved GW Pharma's Epidyolex as a treatment for seizures in two rare and severe forms of epilepsy. The drug won FDA approval last year.
GW’s cannabinoid-based Epidiolex scores another Phase III epilepsy victory
The drug showed positive results in a 210-patient study in patients experiencing treatment-resistant seizures from tuberous sclerosis complex, a rare form of epilepsy.
presented by
Why Your Patients Are Leaving and How to Stop It
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.